1161. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

1162. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.

1163. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma

1164. Hodgkin’s disease with lymphocyte predominance: long-term results based on current histopathologic criteria

1165. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome

1166. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study

1167. American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma

1168. 2608 A retrospective study of vascular thromboembolic events (VaTEs) in patients receiving first line treatment for advanced urothelial cancer (AUC)

1169. Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma: 36

1170. Endocardial metastases as the only site of relapse in a patient with bladder carcinoma: a case report and review of the literature

1171. Renal insufficiency and failure

1172. Validation of the International Prognostic Scoring System (IPSS) for Waldertstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH)

1173. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.

1174. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy

1175. Developments in the systemic treatment of endometrial cancer

1176. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)

1177. Clinical problem-solving: Costly errors

1178. A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP

1179. 9Complications and supportive therapy of multiple myeloma

1180. The changing landscape of smoldering multiple myeloma: a European perspective